Page 4 - Pfizer

Pfizer suspends sale of three antibiotics in India over technical issues

Investigating matter with contract manufacturer Astral Steritech, says pharma firm

Pfizer suspends sale, use of some products in India over quality concerns

Stockists have been asked not to sell, distribute, or use the products until further notice from Pfizer

Pfizer consolidated net profit rises 3% to Rs 130 crore in March quarter

The company said its board recommended a final dividend of Rs 35 per share of Rs 10 each

Pfizer pouring windfall profits from Covid-19 vaccine into cancer battle

The U.S. government will end the COVID Public Health Emergency on Thursday that allowed millions of Americans to receive vaccines, tests and treatments at no cost

Pfizer beats profit estimates as new drugs offset Covid products slump

Pfizer expects 2023 to be a "transition year" for its Covid products, before potential returning to growth in 2024

Pfizer's new bivalent mRNA Covid booster vax highly effective: Lancet

The team found that those who received the bivalent booster dose had a 72% lower risk of Covid related hospitalisation and a 68% lower risk of Covid related death

Seagen acquisition: Pfizer can now bet on future of cancer drugs

Given the muted response to the deal on Monday, analysts seem skeptical that this will be as easy as Pfizer makes it sound

Pfizer to acquire Seagen for $43 bn to deepen reach into treating cancer

Pfizer will spend USD 43 billion to buy Seagen and deepen its reach into treating cancer. The pharmaceutical giant said Monday that it will pay USD 229 per Seagen share. Together, Pfizer and Seagen seek to accelerate the next generation of cancer breakthroughs and bring new solutions to patients by combining the power of Seagen's antibody-drug conjugate (ADC) technology with the scale and strength of Pfizer's capabilities and expertise," Pfizer Chairman and CEO Dr. Albert Bourla said in a statement. Bothell, Washington-based Seagen Inc. is a biotech drug developer. Its key products use monoclonal antibodies that bind to the surface of a tumour cell to deliver a cancer-killing agent while sparing surrounding healthy tissue. Monoclonal antibodies are lab-made proteins delivered mostly by IV at an infusion center, according to the Cleveland Clinic. Seagen's top seller, Adcetris, treats lymph system cancers. It brought in USD 839 million in sales last year, a 19 per cent increase over

Pfizer enters talks to buy Seagen for over $30 billion, says report

Deal will help the firm add to its line-up of cancer treatments

HC directs firm to pay Rs 2 crore damages to Pfizer for contempt of court

The Delhi High Court has directed a firm to pay Rs 2 crore as damages to pharma giant Pfizer Inc for committing wilful" and "contumacious contempt of court by disobeying its order. The court said if the director of the firm, Triveni Interchem Pvt Ltd, fails to pay the amount in two weeks, he shall be taken into custody and detained in a civil prison for two weeks at Tihar jail here. The court, in an interim order, had restrained the firm from making, selling, distributing, advertising, exporting or importing or dealing with any product having compound Palbociclib' or any pharmaceutically acceptable salt as it would infringe the patent of plaintiff Pfizer. As the firm was found continuing to sell Palbociclib, the court held the defendants guilty of wilful disobedience of its order and committing contempt of court. In these circumstances, as the defendants were completely unwilling to acknowledge the fact that it was selling Palbociclib, the court was constrained to hold the defendan

Patent infringement: HC orders Triveni Chemicals to pay Rs 2 cr to Pfizer

Pfizer Inc. and its group companies had filed a suit in the court against Triveni Interchem Private Limited & others accusing the for infringing their patent(IN 218291) for the compound Palbociclib

Pfizer predicts bigger-than-expected sales drop for two key products

Pfizer surprised Wall Street with a prediction for a bigger-than-expected sales drop this year for two key products: its COVID-19 vaccine and treatment. The drugmaker also released an earnings forecast that is below analyst expectations, sending shares lower before the opening bell Tuesday. Pfizer expects sales of both the vaccine Comirnaty and the treatment Paxlovid to tumble next year before starting to rebound. That drop was expected as the drugmaker shifts from supplying government contracts to sales on the commercial market in the United States. But Pfizer said Tuesday that it expects Comirnaty sales to tumble 64% to about $13.5 billion this year. It predicts a 58% drop for Paxlovid to about $8 billion. Wall Street expects more than $14 billion in sales from Comirnaty and another $10.5 billion from Paxlovid, according to FactSet. Overall, Pfizer predicts that adjusted earnings will range between $3.25 and $3.45 per share in the new year. Analysts forecast earnings of $4.34

Biggest challenge during pandemic was negotiating politics: Pfizer

Protectionism as a result of fear meant the governments closed down borders, making it difficult to export vaccines, says Albert Bourla, Pfizer's chief executive officer

Pfizer bivalent Covid shot linked to strokes in ppl 65 & older: Prelim data

The potential risk with Pfizer's vaccine was not seen in other safety databases, nor was it seen with Moderna Inc.'s Covid vaccine, the officials said in a statement

Pfizer CEO rules out talk with China on generic Covid drug Paxlovid license

Bourla said the company had shipped thousands of courses of the treatment in 2022 to China and in the past couple of weeks, had increased that to millions

China, Pfizer hit deadlock over Paxlovid's price amid Covid-19 surge

Pfizer and the government agency that oversees the state medical insurance program failed to agree on a further cut on the price of Paxlovid

Pfizer announces 12-week paternity leave policy for its employees

The policy that came into effect on January 1, 2023, gives biological and adoptive fathers the option to take leaves in up to four tranches

Beijing to distribute Pfizer antiviral drug amid unprecedented Covid wave

Beijing will begin distributing Pfizers Covid 19 drug Paxlovid to the citys community health centres in the coming days, state media reported on Monday

Glenmark Pharma inks settlement pact with Pfizer for cancer treatment drug

Glenmark Pharmaceuticals on Tuesday said it has entered into a settlement agreement with Pfizer Inc regarding a cancer treatment drug. The Mumbai-based drug maker and its US-based unit have inked a settlement pact with drug major Pfizer Inc for Axitinib Tablets (1 mg and 5 mg). Glenmark's product is the generic version of Pfizer's Inlyta tablets, used to treat kidney cancer. According to IQVIATM sales data for the 12-month period ending September 2022, the Inlyta tablets (1 mg and 5 mg) achieved annual sales of around USD 644.5 million. Glenmark said its current portfolio consists of 177 products authorised for distribution in the US marketplace and 47 abbreviated new drug applications (ANDA's) are pending for approval with the US Food and Drug Administration. Shares of of the drug maker were trading 1.54 per cent up at Rs 417.9 apiece on BSE.

Balenciaga joins other brands in quitting Twitter after Musk's takeover

Other companies have paused advertising on the platform, including General Motors, Volkswagen, Pfizer and General Mills.